Excellos

Excellos is a unique full-service CDMO that pairs the collection of critical human cells and tissues with manufacturing and development services to drive innovation in the cell and gene therapy industry. Built on the foundation of the San Diego Blood Bank, with over 70 years of experience in blood and tissue collection and handling, Excellos is focused on supplying cGMP cellular products and services, together with process development and manufacturing expertise to scientists and clinicians working with cell and gene therapies. Our relationship with the San Diego Blood Bank provides exclusive access to one of the largest and most diverse donor pools available, deep institutional expertise, and connection to a public cord blood bank. Excellos pairs this extraordinary resource with dedicated research and development capabilities to isolate, characterize, store, and transport human cell and tissue samples with the highest quality and viability, setting a new standard across the industry. Based in San Diego, Excellos serves the entire cell and gene therapy industry on a global scale, focusing on therapies in preclinical through phase II/III, and always with a clear scale-up pathway to support commercial level operations. Excellos is dedicated to improving human life by leveraging donor populations for life science research and the next generation of cell and gene therapies. Our goal is to facilitate the advancement of cellular therapies and help fully realize the potential of these powerful therapeutics, saving lives today and improving life tomorrow.

Avenzo Therapeutics

Developing the next generation of oncology therapies for patients.

Protego Biopharma

Protego Biopharma focuses on the discovery and development of small-molecule therapeutics that aim to reprogram protein folding for the treatment of various diseases. We are building upon our expertise in the proven pharmacological chaperone approach exemplified by tafamidis, the first marketed disease modifying agent for the treatment of a systemic amyloidosis. The incorporation of the latest advances in biology, chemical biology, biomarkers, structure biology, computation into our approach allows us to expand our disease scope and generate the best therapeutics possible. Our expertise allows us to focus upon generating the key preclinical data that will have clinical translation within the pharmacological chaperone approach. We have assembled a proven team of experts in discovery and development of small molecule pharmacological chaperones and protein homeostasis modulators. This team has joined forces with world-class investors and collaborators who embrace our mission.

VitroLabs Inc

We cultivate authentic materials without compromise,by harnessing science and nature responsibly by partnering the most innovative minds in science and technology with the finest craftspeople to accelerate the use of cellular agriculture for good. Our first product is slaughter-free, real leather.

PrognomiQ Inc

PrognomiQ aims to generate proteomic information with high accuracy, scale and speed. This proteomic data will be complemented with genomic, metabolomic and other health information to deliver first-in-class test products that enable early disease detection and treatment. Powerful, Untapped Disease Insights Built on a Proteomics Foundation: Until now, there have been major technical and economic barriers to broad-scale proteomics analyses, leaving this rich resource of molecular information largely untapped for clinical purposes. These barriers have now been largely addressed through next generation tools that can elucidate complex proteomics at scale. Complementary Molecular Information: Genomic data has made clear contributions to researchers’ abilities to understand and more precisely treat disease, but it is has shown limited impact on early-stage disease detection. Proteomics provides direct information on the biological state of a cell, including disease at its earliest state, but proteomics data has been technically difficult to generate – until now. By complementing the new sources of proteomics data with genomics and other data, such as metabolomics, we now have the tools to generate powerful multi-omics data that will be the key to unlock the detection and treatment of disease at its earliest stages, when these diseases are most likely to be cured. Unlocking Disease Detection and Treatment with Multi-omics Data: We designed our proprietary multi-omics platform around the most robust approaches to generating proteomic, genomic and metabolomics data at scale, including the use of the Proteograph technology platform from the life science tools company Seer (NASDAQ: SEER) whom PrognomiQ spun out of in 2020.